(S)-2-(((Benzyloxy)carbonyl)amino)-6-ureidohexanoic acid

Catalog No. :
ACELCV365
CAS No. :
57533-91-2
Molecular Formula :
C15H21N3O5
Molecular Weight :
323.35

IUPAC Name:N2-((benzyloxy)carbonyl)-N6-carbamoyl-L-lysine

(S)-2-(((Benzyloxy)carbonyl)amino)-6-ureidohexanoic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g98%$459.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(S)-2-(((Benzyloxy)carbonyl)amino)-6-ureidohexanoic acid
IUPAC NameN2-((benzyloxy)carbonyl)-N6-carbamoyl-L-lysine
MDL No.MFCD00191271
Molecular FormulaC15H21N3O5
Molecular Weight323.35
SMILESO=C(O)[C@@H](NC(OCC1=CC=CC=C1)=O)CCCCNC(N)=O
InChI KeyGDAQVXISDUMUJG-LBPRGKRZSA-N
SynonymZ-Homocit-OH;Z-Hci-OH, Z-Lys(carbaMoyl)-OH;(S)-2-(((BENZYLOXY)CARBONYL)AMINO)-6-UREIDOHEXANOIC ACID;L-Lysine, N6-(aminocarbonyl)-N2-[(phenylmethoxy)carbonyl]-;N-α-Carbobenzoxy-L-homocitrulline;(2S)-6-(carbamoylamino)-2-(phenylmethoxycarbonylamino)hexanoicacid
CAS No.57533-91-2

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H312-H332
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P330-P363-P501

Synthetic Route by SureRoute

1. ACELCV365 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACEFWU937 route compound structure diagram
    ACEFWU9371190-49-4 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACELCV365 route product structure diagram
    ACELCV36557533-91-2
Inquiry

2. ACELCV365 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACEFWU937 route compound structure diagram
    ACEFWU9371190-49-4 In Stock
  2. Plus
  3. ACPLJU502 route compound structure diagram
    ACPLJU50231139-36-3 In Stock
  4. Then
  5. ACELCV365 route product structure diagram
    ACELCV36557533-91-2
Inquiry

Comments (0)